SEC 13F Intelligence

Deuterium Capital Management, LLC / CRSP

Deuterium Capital Management, LLC’s Crispr Therapeutics AG Position

Does Deuterium Capital Management, LLC own Crispr Therapeutics AG (CRSP)? Yes — 25.0K shares worth $1M (+1.38% of its 13F portfolio) as of Q1 2026, up from 18.0K shares the prior filed quarter.

Position Value
$1M
Q1 2026
Shares
25.0K
% of Portfolio
+1.38%
Quarters Held
3
currently held

Position History CRSP

Reported value by quarter
Q4 ’21: $1MQ4 ’21Q1 ’22: $1MQ1 ’22Q1 ’26: $1MQ1 ’26filingsflow.com
QuarterSharesValue% of Portfolio
Q1 202625.0K$1M+1.38%
Q1 202218.0K$1M+1.45%
Q4 202118.0K$1M+2.02%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Deuterium Capital Management, LLC’s full portfolio or all institutional holders of CRSP.